StockData
Neumora Therapeutics, Inc. logo

Neumora Therapeutics, Inc. (NMRA) stock

NMRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 2/30
$0.33−0.03 (-9.47%)

Close on Nov 17, 2026Market cap $62.85MP/E –Yield –

Neumora Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Neumora Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$211.23M. For fiscal 2025 it was -$241.16M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$241.16M–
FY2024Dec 31, 2024-$263.46M–
FY2023Dec 31, 2023-$252.10M–
FY2022Dec 31, 2022-$135.87M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$42.19M–
Q1 FY2026Mar 31, 2026-$52.86M–
Q4 FY2025Dec 31, 2025-$58.48M–
Q3 FY2025Sep 30, 2025-$57.70M–
Q2 FY2025Jun 30, 2025-$54.04M–
Q1 FY2025Mar 31, 2025-$70.94M–
Q4 FY2024Dec 31, 2024-$62.92M–
Q3 FY2024Sep 30, 2024-$76.65M–
Q2 FY2024Jun 30, 2024-$63.82M–
Q1 FY2024Mar 31, 2024-$60.07M–
Q4 FY2023Dec 31, 2023-$114.00M–
Q3 FY2023Sep 30, 2023-$56.86M–
Q2 FY2023Jun 30, 2023-$42.06M–
Q1 FY2023Mar 31, 2023-$39.17M–
Q4 FY2022Dec 31, 2022-$30.72M–
Q3 FY2022Sep 30, 2022-$30.60M–

More Neumora Therapeutics figures

See a number that looks wrong?